Taldefgrobep Alfa: Biohaven's Bet on Muscle-Preserving Weight Loss

It failed before it pivoted. Taldefgrobep alfa missed its primary endpoint in spinal muscular atrophy, but the body-composition data tucked inside that failure was strong enough that Biohaven re-launched it as a muscle-sparing obesity candidate the same year.

Quick facts on taldefgrobep alfa

For context on the broader race, see myostatin inhibitor obesity and myostatin glp-1 muscle loss.

What makes taldefgrobep different

It is not a regular antibody. Most anti-myostatin drugs (apitegromab, trevogrumab, MYO-029, domagrozumab) are monoclonal antibodies. Taldefgrobep is an adnectin, a small engineered protein built on a human fibronectin scaffold.

That shape matters in two ways:

1. Adnectins are smaller, which can change tissue distribution and binding kinetics.
2. The molecule binds myostatin and forms stable complexes that competitively block activin type II receptor signaling, so it acts a layer downstream as well.

Functionally, the drug both lowers free myostatin and blocks the receptor signal that the remaining myostatin would otherwise trigger.

The history: from BMS to Biohaven

The molecule has been around. Bristol Myers Squibb developed BMS-986089 internally, ran early SMA studies, and then out-licensed the program to Biohaven in 2022 as part of a broader portfolio cleanup.

Biohaven renamed it taldefgrobep alfa and built the phase 3 program around SMA, leveraging the existing safety database. The bet at the time was that a muscle-anabolic drug layered onto SMN-restoring therapies (nusinersen, risdiplam, onasemnogene abeparvovec) would meaningfully improve motor function in pediatric SMA.

That bet did not pay off cleanly.

The Phase 3 RESILIENT trial in SMA

The failure was specific. RESILIENT enrolled 269 patients aged 4 to 21 across 53 sites in nine countries, including both ambulatory and non-ambulatory patients across all SMA types. Everyone was on stable SMN-upregulator therapy.

Dosing was weight-based subcutaneous: 35 mg weekly for patients weighing 15 to 40 kg, 50 mg weekly for those over 40 kg. The primary endpoint was change in MFM-32 (32-item Motor Function Measure) total score from baseline to week 48.

The drug missed that primary endpoint. There was no statistically significant benefit across the overall study population.

What was buried in the subgroup data

But the trial was not a clean miss. A handful of secondary and subgroup findings looked striking:

• Caucasian patients (87 percent of the trial population) showed a 2.2-point MFM-32 improvement versus 1.1-point for placebo, with p less than 0.039.
• Caucasian patients with measurable baseline myostatin levels showed a 1.4-point placebo-adjusted benefit (p=0.02).
• 50 percent of myostatin-positive Caucasian patients were responders (defined as a 3-point or greater MFM-32 change) versus 30 percent on placebo.
• Total body fat mass dropped significantly (p=0.008) across the full population.
• Lean mass and bone density rose numerically.
• 97 percent of patients continued into the open-label extension, with no serious adverse events tied to the drug.

The body-composition data is what saved the program. Significant fat-mass loss plus numerical lean-mass gain in a multi-month pediatric trial was exactly the safety-efficacy profile Biohaven could re-pitch for obesity.

The pivot to obesity

The switch was fast. By mid-2025 Biohaven was openly discussing an obesity phase 2, and by early 2026 the trial was fully enrolled.

NCT07281495 is the new lead study:

• About 150 adults across roughly 20 US sites.
• BMI greater than 30 or BMI 27 or higher with comorbidities.
• Ages 18 to 65.
• Excludes diabetes, non-ambulatory status, pregnancy, and concurrent obesity trials.
• Quadruple-masked, placebo-controlled, parallel-arm design.
• Four arms: taldefgrobep weekly, taldefgrobep monthly, weekly placebo, monthly placebo.
• 24-week primary treatment period plus a 24-week open-label extension.
• Primary endpoint: percent change in total body weight from baseline to week 24.
• Secondary endpoints: body fat mass, lean mass, and safety through week 24.

Topline data is expected in the second half of 2026. A positive monotherapy signal would unlock combination studies with semaglutide and tirzepatide in 2027.

How the obesity bet actually works

The thesis is narrow. Dr. Pete Ackerman, Biohaven's senior vice president of clinical development, summarized it bluntly: "Not everyone is looking to lose 25 or 30 percent of their total body weight."

What he means is the lean-mass case. Most patients on Wegovy or Zepbound lose enough weight; the problem is that 25 to 40 percent of that loss is muscle. Taldefgrobep is being positioned as a "higher-quality weight loss" option, either as a monotherapy for patients who prefer a slower body-composition recomposition or as an add-on to a GLP-1 for those already on one.

The autoinjector form factor matters. Self-administered subcutaneous dosing once a week or once a month is the right shape for an obesity drug. Bimagrumab's IV infusion is the wrong shape, and that may be one of taldefgrobep's quiet advantages.

Dosing and administration

In SMA Phase 3:

• Subcutaneous, once weekly.
• 35 mg for body weight 15 to 40 kg.
• 50 mg for body weight over 40 kg.

In the obesity phase 2:

• Subcutaneous, self-administered via autoinjector.
• Either once weekly or once every four weeks (two of the four study arms test the monthly schedule).
• Specific milligram doses for adults are not publicly disclosed in the trial record but are weight-banded similar to SMA dosing.

Side effects so far

The drug looked tolerable in SMA. No serious adverse events were reported in RESILIENT, 97 percent of patients continued into the open-label extension, and the side-effect profile in the obesity phase 2 has not been published.

Across the anti-myostatin antibody class, common findings include muscle spasms, mild diarrhea, transient liver-enzyme and creatine-kinase elevations, and occasional acne. Adnectin-class drugs may have a different profile than monoclonal antibodies, but obesity data is needed before that can be confirmed.

How taldefgrobep compares to the field

The most useful framing: bimagrumab is the most potent, apitegromab is the cleanest, taldefgrobep is the most patient-friendly to dose, and trevogrumab is the highest variance.

What investors are watching

Five things will move Biohaven's stock through 2026 and 2027.

1. The H2 2026 topline from the obesity phase 2.
2. Whether weekly versus monthly dosing produces the same lean-mass effect.
3. Whether the safety profile from RESILIENT carries into adults at obesity doses.
4. The FDA conversation on a registration path that uses lean-mass preservation as an endpoint.
5. Any partnership announcement with a GLP-1 sponsor (Lilly, Novo Nordisk, or Pfizer) that would fund combination studies.

The negative case is also clean. A miss on the obesity phase 2 primary endpoint would leave Biohaven without a path forward for taldefgrobep, since the SMA program is functionally finished. The drug effectively has one more swing.

Realistic status in May 2026

The honest read: taldefgrobep is alive, enrolled, and high-stakes. It has a credible mechanism, a serviceable safety profile, and a form factor that fits the obesity market better than most rivals. It is also one trial away from being shelved if H2 2026 reads out poorly.

The market has priced that uncertainty into Biohaven's valuation. Anyone reading this as a patient should not expect taldefgrobep to be prescribable before 2028 at the earliest.

Sources and notes

• Biohaven Phase 2 Obesity Study with Taldefgrobep Alfa Completes Enrollment - PR Newswire
• Biohaven fails phase 3 SMA test, plots move to obesity - Fierce Biotech
• Taldefgrobep Alfa Yields Encouraging Subgroup Signals - NeurologyLive
• Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy - MDPI
• Myostatin Inhibition Platform - Biohaven
• P04 Taldefgrobep alfa early and clinical data - ScienceDirect
• Obesity drugmakers chase weight loss; Biohaven is betting on muscles - PharmaVoice
• Taldefgrobep Alfa in Adults With Overweight and Obesity - NCT07281495
• Emerging Role of Myostatin Inhibitors in the Management of Glucagon - PMC

Frequently Asked Questions